Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
about
Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumorsTargeted therapy of gastrointestinal stromal tumoursSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesSomatic DNA mutation analysis in targeted therapy of solid tumoursMore than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsReview article: the biology, diagnosis and management of gastrointestinal stromal tumoursUniverses collide: combining immunotherapy with targeted therapy for cancerClinical practice guidelines for patients with gastrointestinal stromal tumor in TaiwanDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.Approaches to modernize the combination drug development paradigmUpdate on clinical research and state of the art management of patients with advanced sarcomas and GISTUnveiling changes in the landscape of patient populations in cancer early drug developmentAdvanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendationsPazopanib in the treatment of soft tissue sarcomaPazopanib, a new therapy for metastatic soft tissue sarcomaWee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomasFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentKey messages from the BFR14 trial of the French Sarcoma Group.Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.Strategies for modern biomarker and drug development in oncology.Discovered on gastrointestinal stromal tumours 1 (DOG1) expression in non-gastrointestinal stromal tumour (GIST) neoplasms.Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsAnalysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistanceIncreased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumorAbsence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesImatinib-induced pleural effusion: A case report.Gastrointestinal stromal tumor and its targeted therapeutics.UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trialComparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.Imatinib: a breakthrough of targeted therapy in cancer.Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort studyTargeted therapy for cancer: the gastrointestinal stromal tumor model.A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
P2860
Q26738567-753D81FC-BA85-461D-92CC-B9635A2A5E0EQ26745633-92A1FE9F-1AC6-495B-80CB-058D152780BCQ26751274-A78DE1AF-B2DB-45AF-A81D-568C8B12B3B4Q26770324-56B96B8E-B918-4A20-8AF8-E78F6C528740Q26781662-941FEA9F-D3E0-474A-BA65-7EED3101D4AEQ26825310-736B27F2-705E-4467-8F34-4CD1CE2A115DQ26825316-C1D28119-05DA-4DD2-B158-AC152C6FA883Q27027632-799B73F2-DCDF-46BB-A5B0-51F5E2E582C0Q27851628-CB0BFCE2-F9EA-4627-A746-5BD63427D4A7Q27853181-DC512C5F-C16C-48CE-A78F-7146C9EF4A29Q28072074-C5E88D8C-DBA7-4C6B-A0D4-FCBE3264D348Q28073290-EA010709-4293-4A04-B3A6-D3CFFBB31FCAQ28073826-D8709E4D-DD3D-411F-B965-ABD8534F9300Q28247449-8168C5A7-076E-405E-B6F1-683D31E1E1C5Q28269229-7E2B9A4D-F408-4631-989B-5CB73E103B8EQ28287163-DE1ACA1B-2EC3-4E42-8184-69FC13ACCA75Q28487835-74CE2B6F-A93E-43EA-9AD2-E27743A6F464Q28533949-1EAA8956-DA9D-4AD5-9132-1F57D8EFF6D2Q30245384-825821D0-0969-45EE-B261-05A050D0C02DQ30245586-96A7983F-934B-4984-94D1-7D9215298BDBQ30485073-5C2B7CDD-533E-474F-A4F9-9CF7344B6AC6Q30590270-79200AC6-032A-4154-B238-4343B57AC0E1Q33274455-8E0A9526-7CAC-4603-B625-310331353555Q33412724-2143AE58-52D7-4FB1-8656-BED885EDCD32Q33549674-98D96788-8DB3-4EA5-98FF-A931529B32B7Q33560776-AE5EC398-7F66-4612-B06A-2F5B33ACEF59Q33561602-949FBDF9-4BF8-45D0-9E11-2FA02FCBA282Q33572971-1E3355DB-2064-4B96-BFAE-495A6A8423E9Q33573367-D791B949-AF71-4B59-BA26-176FB710EA1DQ33579642-C94DA114-7963-465E-9B86-491FF66C19F9Q33612778-AE67EC7E-F139-4920-B6A7-B52E4F5EEEDFQ33633409-7630A04D-BDFD-40C3-8105-194C98A668D3Q33644791-B916F33E-E21B-4CD3-A37F-CAFD5EFC24C0Q33699901-21DB04D5-C819-48D4-AC8D-E049B53C43FEQ33710999-E21D2B00-EFBB-408E-AA50-7F648D292C0BQ33747261-C642065B-0236-4989-90EA-D8941BC9452AQ33756542-1487A922-C5B4-4873-A1E7-1672C9F3D60DQ33807742-00DBE377-1536-4FA5-91DB-D779B86FA5ACQ33817421-DB6C29CF-833C-4F59-830A-4E77485FAC73Q33889152-582E45DA-78D9-4162-8647-6BB789D6FC21
P2860
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Phase III randomized, intergro ...... ceptor tyrosine kinase: S0033.
@ast
Phase III randomized, intergro ...... ceptor tyrosine kinase: S0033.
@en
Phase III randomized, intergro ...... ceptor tyrosine kinase: S0033.
@nl
type
label
Phase III randomized, intergro ...... ceptor tyrosine kinase: S0033.
@ast
Phase III randomized, intergro ...... ceptor tyrosine kinase: S0033.
@en
Phase III randomized, intergro ...... ceptor tyrosine kinase: S0033.
@nl
prefLabel
Phase III randomized, intergro ...... ceptor tyrosine kinase: S0033.
@ast
Phase III randomized, intergro ...... ceptor tyrosine kinase: S0033.
@en
Phase III randomized, intergro ...... ceptor tyrosine kinase: S0033.
@nl
P2093
P356
P1476
Phase III randomized, intergro ...... eceptor tyrosine kinase: S0033
@en
P2093
A Kevin Raymond
Cathryn Rankin
Charles D Blanke
Christopher D M Fletcher
Christopher W Ryan
Ernest C Borden
George D Demetri
J Randolph Hecht
John J Crowley
Laurence H Baker
P304
P356
10.1200/JCO.2007.13.4452
P407
P577
2008-02-01T00:00:00Z